The Latest

• 

  Podcast

  Woman of the Week: Novartis Gene Therapies’ Chris Fox

  Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...

  Biotech

• 

  Sponsored by Adheris Health

  Changing the channel from TV to the pharmacy boosts DTC ROI

  While a TV spot still has its allure, the level of engagement provided through the pharmacy channel is more than a little compelling.

  Pharma

• 

  Profile

  A rising oncology powerhouse in China, BeiGene looks to strengthen its international punch

  To expand its reach, Christiane Langer, the company’s head of medical affairs, is leaning on connections and singularity over fitting in a box.

  Biotech

• 

  Profile

  The power of connections for a startup CEO

  Priyanka Dutta-Passecker, head of wound-care specialist Healiva, discusses the importance of tapping her network in starting and running a biotech.

  Biotech

• 

  Biden doubles down on drug pricing in 2024 budget — but boosts R&D

  The president’s 2024 budget proposal expands on last year’s drug pricing reforms, but also dramatically increases innovation investments.

  Biotech

• 

  Q&A

  Babson aims to shed Theranos curse with new blood testing tech

  Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?

  Biotech

• 

  Q&A

  IQVIA’s OG of data analytics on the latest clinical trial trends

  IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.

  Patient

• 

  Q&A // Biotech Spotlight

  While many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer

  The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.

  Biotech Spotlight

• 

  Janssen neuroscience leader takes on rare diseases one small ‘eureka’ at a time

  Fueled by a fascination with the scientific process, Sindhu Ramchandren is exploring how a new drug could treat patients with a range of rare diseases.

  Leadership

• 

  Targeting the new ‘Golden Girls’

  With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.

  Biotech

• 

  Podcast

  Woman of the Week: Lucy Therapeutics’ Amy Ripka

  How a 3.2-million-year-old fossil inspired the CEO to unlock the mysteries of mitochondrial dysfunction.

  Biotech

• 

  Eli Lilly took price cuts into its own hands. Will other pharmas follow suit?

  The pharma giant took the high road and cut prices before the feds made them. How will that affect the industry?

  Biotech

• 

  3 keys to good storytelling in pharma

  The CEO of Complement Therapeutics shares simple storytelling tactics lead to maximum impact.

  Biotech

• 

  Why layoffs are not the answer to biopharma’s troubled market

  As companies look to cut costs, an EY analyst urges them to consider not cutting staff.

  Biotech

• 

  FDA ups generics and biosimilar approvals for a shot at lower drug costs

  As the Biden administration searched for drug-cost reducing measures, the FDA incentivized generic and biosimilar development in 2022. 

  Policy & Regulation

• 

  PharmaVoice 100 honorees: Where are they now?

  How some of our past PharmaVoice 100 honorees are transforming the life sciences industry in new roles. 

  Biotech

• 

  Q&A // First 90 Days

  The ‘recovering academic’ leading Allogene to the next stage of cell therapy

  Zachary Roberts joined Allogene at the beginning of this year to lead the company's R&D and bring allogeneic cell therapy to the forefront.

  Biotech

• 

  Q&A // Biotech Spotlight

  Launched with a ‘pioneer’ in RNA, aTyr Pharma is charting a new course in immunology

  With a focus on rare and hard-to-treat diseases, aTyr is banking on its head start in tRNA and vast IP portfolio to build a billion-dollar company.

  Biotech Spotlight

• 

  Do R&D costs justify the price of drugs? Nope, new study says

  A BMJ study found that spending on drug sales vastly outstripped spending on drug development.

  Biotech

• 

  Podcast

  Woman of the Week: Denali Therapeutics’ Cindy Dunkle

  As chief people officer, Dunkle is harnessing the company’s unique culture to foster innovation.

  Biotech

• 

  Multimillion-dollar therapies are changing how payers foot the bill

  With more gene therapies headed to market, novel payment methods are emerging from regulators and academia. 

  Biotech

• 

  Reata’s stock plummets amid sudden FDA neuro office shakeup

  The FDA’s longtime neuroscience head Billy Dunn stepped down, leaving industry reeling over how the agency’s new acting director could handle upcoming approval decisions.

  Biotech

• 

  Who is Vivek Ramaswamy — the biotech entrepreneur turned presidential candidate?

  The former CEO of Roivant, who became the face of the “anti-woke” business movement, is now running for the 2024 Republican presidential nomination. Here’s what he stands for. 

  Biotech

• 

  As clinical trials face a hiring crunch, here’s how research organizations can pivot

  Staffing shortages are causing inefficiencies in clinical trials, but one leading CRO is finding ways to adapt.

  Biotech

• 

  Q&A // Biotech Spotlight

  Cytokinetics looks to muscle into the cardiovascular market

  With a scientific platform based on muscle biology, the late-stage biotech is addressing cardiovascular and neuromuscular diseases.

  Biotech

• 

  Why FDA’s approach to orphan drug exclusivity is ripe for more legal challenges

  Despite a court ruling, the FDA is sticking to its narrow orphan drug exclusivity approach. But confusion remains over the policy’s future. 

  Pharma